ProCE Banner Activity

My Experience Managing Key Adverse Events With Oral Targeted Therapy for High-Risk Early Breast Cancer

Clinical Thought

An expert highlights key adverse events with oral targeted therapy options for high-risk early breast cancer and management strategies. 

Released: December 06, 2023

Share

Faculty

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Professor of Medicine
Director, Glenn Family Breast Center
Winship Cancer Institute
Emory University
Atlanta, Georgia

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme, LLC and AstraZeneca.

AstraZeneca

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Kevin Kalinsky, MD, MS

Professor of Medicine
Director, Glenn Family Breast Center
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini, Merck, Mersana, Myovant Sciences, Puma Biotechnology, Seattle Genetics, Silicon Biosystems, Takeda.